Targeted Delivery of Cytotoxic Drugs: Challenges, Opportunities and New Developments.

Targeted Delivery of Cytotoxic Drugs: Challenges, Opportunities and New Developments.
复制标题

DOI:
10.2533/chimia.2017.712
复制
发表时间:
2017-10-25
期刊:
影响因子:
1.2
通讯作者:
Neri D
Neri D
中科院分区:
化学4区
文献类型:
--
作者:
Cazzamalli S;Corso AD;Neri D

文献摘要

参考文献

被引文献

相似文献

细胞毒性药物通常用于多种癌症的药物治疗,通常会对患者造成严重的毒性,而无法引起持久的缓解。可接近的肿瘤相关靶点的特异性配体,能够在肿瘤部位选择性定位,可能促进抗癌药物的优先递送,增强活性并帮助保留正常器官。在本文中,我们对传统抗癌药物的局限性进行了批判性分析,并对比了单克隆抗体和小有机配体作为药物递送应用的载体。
Cytotoxic drugs, which are commonly used for the pharmacotherapy of many forms of cancer, often cause substantial toxicity to the patient without being able to induce long-lasting remissions. Ligands specific to accessible tumor-associated targets, capable of selective localization at the neoplastic site, may facilitate the preferential delivery of anti-cancer drugs, boosting activity and helping spare normal organs. In this article, we present a critical analysis of the limitation of conventional anti-cancer drugs and we contrast monoclonal antibodies and small organic ligands, as vehicles for pharmacodelivery applications.
DOI: 10.1158/1535-7163.mct-16-0283
发表时间: 2016-12
影响因子: 5.7
作者:
Cazzamalli S;Dal Corso A;Neri D
通讯作者: Neri D
DOI: 10.1073/pnas.89.12.5381
发表时间: 1992-06-15
影响因子: 11.1
作者:
BRENNER, S;LERNER, RA
通讯作者: LERNER, RA
DOI: 10.1016/j.drudis.2015.10.012
发表时间: 2016-01
影响因子: 7.4
作者:
Bootz, Franziska;Neri, Dario
通讯作者: Neri, Dario
DOI: 10.1158/1078-0432.ccr-11-0488
发表时间: 2011-10-15
影响因子: 11.5
作者:
Katz, Jessica;Janik, John E.;Younes, Anas
通讯作者: Younes, Anas
DOI: 10.1021/jm100729b
发表时间: 2010-11-11
影响因子: 7.3
作者:
Kularatne, Sumith A.;Venkatesh, Chelvam;Low, Philip S.
通讯作者: Low, Philip S.